You may know someone on Ozempic or Wegovy, or have tried a GLP-1 drug yourself. Most people brace for nausea or stomach trouble when they start. Few expect their nails to start lifting away from the finger.
A new study presented at the European Academy of Dermatology and Venereology Congress 2026 in Vienna found that 39% of GLP-1 users had experienced nail detachment. That is when the nail plate separates from the nail bed.
In a comparison group of similar people who had never used the drugs, just 9% reported the same problem.
The researchers compared 575 people taking GLP-1 drugs with 1,329 people living with obesity or type 2 diabetes who had never used them. The participants came from France, the United States, Brazil, and Mexico.
Also read: Is alkaline water actually better for you? Here's what the evidence says
GLP-1 drugs, including Ozempic and Wegovy from Novo Nordisk and Mounjaro and Zepbound from Eli Lilly, mimic a gut hormone that curbs appetite and lowers blood sugar.
What the dermatologists actually measured
Two in three GLP-1 users reported at least one nail problem, versus about half of the control group. Nail discoloration was the other standout, affecting nearly half of users. Fewer than one in five non-users said the same.
Hair told a similar story. Half of users reported unusual shedding, well above the rate in controls. About one in four said the loss began after they started treatment. Only 12% of non-users described that pattern.
Scalp redness was roughly three times more frequent among GLP-1 users.
Also read: Five simple exercises to help your body recover from years of sitting
Association, not proof
The researchers were careful about what the numbers can and cannot show. The study is cross-sectional and based on what patients reported, so it cannot prove the drugs cause the nail changes.
"Until now, nail changes associated with GLP-1 therapies had essentially been anecdotal," said Dr. Charles Taïeb, who led the nail analysis.
About half of users reported nail problems that predated their treatment. Even after adjusting for existing skin conditions and nutritional deficiencies, nail detachment and discoloration remained two to three times more common among users than in controls.
Weight loss alone did not fully explain the differences either, the team noted.
Also read: 8 everyday foods that could be quietly raising your kidney stone risk
Where this fits with known side effects
Nausea, vomiting, and diarrhea are the most reported side effects of GLP-1 drugs. In the FDA label for Wegovy, 44% of users reported nausea in trials, roughly triple the rate seen with placebo. Nail and hair complaints have mostly stayed off that list.
The scalp finding may be more than cosmetic. "What is happening on the scalp may go beyond the classical shedding seen after rapid weight loss and involve an inflammatory component," said Dr. Bruno Halioua, who co-led the research.
What this means for people on the drugs
Halioua urged users not to overreact. "These changes are frequent, usually benign, and are not a reason to stop an effective treatment on one's own initiative," he said.
Anyone worried about new nail or hair changes should raise them with the clinician who prescribed the medication, rather than stopping it alone.
Also read: Poor sleep quality linked to 65% higher risk of fatty liver disease, new research shows
The team plans prospective studies that follow patients from the day they start treatment. Standardized skin exams and lab monitoring will clarify what the drugs do to nails and hair.
Also read: What science says about eating one clove of garlic daily
This article is made and published by Jesper Bengtson, who may have used AI in the preparation.